AMPLIA THERAPEUTICS LIMITED - Announcements

2.13%

24.0¢

Market Cap $116.7M

Healthcare Biotechnology

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ATX	First Patient Recruited to ACCENT Trial in Pancreatic Cancer	PRICE SENSITIVE	02/08/22	132.49KB	Share
ATX	Quarterly Activities and Cashflow Reports - June 2022 Qtr	PRICE SENSITIVE	28/07/22	371.69KB	Share
ATX	Presentation at Major Pancreatic Cancer Conference		25/07/22	153.78KB	Share
ATX	Notice of Annual General Meeting/Proxy - YE 31 March 2022		22/07/22	591.2KB	Share
ATX	Change of Director's Interest Notice - Dr. Chistopher Burns		07/07/22	341.79KB	Share
ATX	Change of Director's Interest Notice - Dr. Robert Peach		07/07/22	276.74KB	Share
ATX	Change of Director's Interest Notice - Dr. John Lambert		07/07/22	467.75KB	Share
ATX	Change of Director's Interest Notice - Dr. Warwick Tong		07/07/22	402.32KB	Share
ATX	Notification of cessation of securities - ATX		05/07/22	21.69KB	Share
ATX	Application for quotation of securities - ATX		30/06/22	24.91KB	Share
ATX	Annual General Meeting to be held Thursday 25 August 2022		29/06/22	118.42KB	Share
ATX	Registered Office and Principal Place of Business		24/06/22	127.54KB	Share
ATX	Notification of Expiry of Unlisted Options		09/06/22	210.42KB	Share
ATX	Application for quotation of securities - ATX		09/06/22	24.91KB	Share
ATX	AMP945 Shows Efficacy in Model of Lung Fibrosis	PRICE SENSITIVE	02/06/22	182.84KB	Share
ATX	App 4G - Key to Corporate Governance Disclosures		30/05/22	368.09KB	Share
ATX	2022 Corporate Governance Statement		30/05/22	396.46KB	Share
ATX	Preliminary Final Report and Annual Report YE 31 March 2022	PRICE SENSITIVE	30/05/22	2.92MB	Share
ATX	Amplia Receives Second Ethics Clearance for Phase 2 Trial	PRICE SENSITIVE	13/05/22	158.42KB	Share
ATX	Amplia Presentation to 16th Bioshares Biotech Summit		12/05/22	10.4MB	Share
ATX	AMP945 Pre-IND Meeting Outcome	PRICE SENSITIVE	09/05/22	133.54KB	Share
ATX	Quarterly Activities and Cashflow Reports - March 2022 Qtr	PRICE SENSITIVE	19/04/22	380.29KB	Share
ATX	Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients	PRICE SENSITIVE	06/04/22	187.1KB	Share
ATX	Notification of cessation of securities - ATX		05/04/22	21.66KB	Share
ATX	AMP945 Improves Survival in Human Pancreatic Cancer Model	PRICE SENSITIVE	17/02/22	232.86KB	Share
ATX	ATX Abstract accepted for presentation at Cancer Conference		15/02/22	154.44KB	Share
ATX	Sale of Unmarketable Parcels of Shares		14/02/22	782.73KB	Share
ATX	Change of Director's Interest Notice - Jane Bell		10/02/22	321.86KB	Share
ATX	Amplia Investor Presentation - February 2022		01/02/22	11MB	Share
ATX	Quarterly Activities and Cashflow Reports - Dec 2021 Qtr	PRICE SENSITIVE	24/01/22	412.91KB	Share
ATX	Notification regarding unquoted securities - ATX		19/01/22	27.73KB	Share
ATX	Amplia Completes Manufacture of AMP945 for Planned Trials	PRICE SENSITIVE	13/01/22	133.41KB	Share
ATX	Change in substantial holding		23/12/21	138.28KB	Share
ATX	Application for quotation of securities - ATX		22/12/21	24.88KB	Share
ATX	Application for quotation of securities - ATX		22/12/21	24.93KB	Share
ATX	Change in substantial holding		22/12/21	141.83KB	Share
ATX	App 3Y - Change of Director's Interest - Mrs Jane Bell		21/12/21	322.38KB	Share
ATX	App 3Y - Change of Director's Interest - Dr. Chris Burns		21/12/21	344.52KB	Share
ATX	App 3Y - Change of Director's Interest - Dr. Robert Peach		21/12/21	348.92KB	Share
ATX	App 3Y - Change of Director's Interest - Dr. John Lambert		21/12/21	365.41KB	Share
ATX	App 3Y - Change of Directors Interest Notice - Dr. W. Tong		21/12/21	347.04KB	Share
ATX	Proposed issue of securities - ATX		21/12/21	24.99KB	Share
ATX	Update - Application for quotation of securities - ATX		20/12/21	26.44KB	Share
ATX	Results of Extraordinary General Meeting		17/12/21	207.35KB	Share
ATX	Amplia Provides Updated Investor Presentation	PRICE SENSITIVE	16/12/21	3.01MB	Share
ATX	Change in substantial holding		15/12/21	201.39KB	Share
ATX	Update - Application for quotation of securities - ATX		15/12/21	26.76KB	Share
ATX	Update - Proposed issue of securities - ATX		14/12/21	36.06KB	Share
ATX	Entitlement Offer Completed	PRICE SENSITIVE	10/12/21	105.92KB	Share
ATX	Amplia Awarded $2.1M R&D Cash Flow Loan	PRICE SENSITIVE	02/12/21	131.38KB	Share
ATX	App 4D and Financial Report Half Year ended 30 Sep 2021	PRICE SENSITIVE	24/11/21	868KB	Share
ATX	Notice of Extraordinary General Meeting - 17 Dec 2021		19/11/21	525.78KB	Share
ATX	Summary Results - Successful Phase 1 Clinical Trial AMP945		18/11/21	163.8KB	Share
ATX	Inhibition of FAK by AMP945 in Phase 1 Clinical Trial	PRICE SENSITIVE	17/11/21	134.39KB	Share
ATX	Becoming a substantial holder		16/11/21	80.04KB	Share
ATX	Application for quotation of securities - ATX		15/11/21	25.31KB	Share
ATX	Change in substantial holding		15/11/21	141.19KB	Share
ATX	Application for quotation of securities - ATX		15/11/21	24.92KB	Share
ATX	Section 708A Cleansing Notice - Share Placement		12/11/21	137.62KB	Share
ATX	Blueflag Holding - Change of Interest of Substantial Holder		12/11/21	129.13KB	Share
ATX	Application for quotation of securities - ATX		12/11/21	25.17KB	Share
ATX	Proposed issue of securities - ATX		08/11/21	36.46KB	Share
ATX	Proposed issue of securities - ATX		08/11/21	30.62KB	Share
ATX	Capital Raising Investor Presentation	PRICE SENSITIVE	08/11/21	2.08MB	Share
ATX	Entitlement Offer Prospectus	PRICE SENSITIVE	08/11/21	970.51KB	Share
ATX	Placement and Underwritten Entitlement Offer to Raise $12.4m	PRICE SENSITIVE	08/11/21	230.26KB	Share
ATX	Amplia and CRUK agree to Amend Licence Terms - AMP886		04/11/21	103.46KB	Share
ATX	Trading Halt	PRICE SENSITIVE	04/11/21	234.65KB	Share
ATX	Quarterly Activities and Cashflow Reports - Sep 2021 Qtr	PRICE SENSITIVE	27/10/21	346.77KB	Share
ATX	Amplia Appoints New Oncology Clinical Advisor		26/10/21	130.94KB	Share
ATX	Amplia Provides Updated Investor Presentation	PRICE SENSITIVE	19/10/21	2.44MB	Share
ATX	Amplia Receives $1.1m R&D Tax Incentive	PRICE SENSITIVE	14/10/21	102.7KB	Share
ATX	Amplia Appoints New Chief Financial Officer		01/10/21	100.18KB	Share
ATX	New Garvan Publication Supports Amplia Phase 2 Design	PRICE SENSITIVE	30/09/21	158.96KB	Share
ATX	Proactive Investors Lifesciences Webinar Presentation		28/09/21	1.16MB	Share
ATX	Amplia to Present at Proactive Investor Lifesciences Webinar		27/09/21	106.94KB	Share
ATX	Phase 2 Trial in First-Line Pancreatic Cancer Patients	PRICE SENSITIVE	15/09/21	134.22KB	Share
ATX	Updated Investor Presentation		15/09/21	2.58MB	Share
ATX	Change of Director's Interest Notice - Jane Bell		06/09/21	352.54KB	Share
ATX	Results of Annual General Meeting		27/08/21	150.35KB	Share
ATX	AGM - Chief Executive Officer's Presentatioin	PRICE SENSITIVE	27/08/21	1.4MB	Share
ATX	Annual General Meeting Arrangements		20/08/21	104.63KB	Share
ATX	Quarterly Activities and Cashflow Reports and Presentation	PRICE SENSITIVE	28/07/21	2.4MB	Share
ATX	Shareholder Update and Presentation		26/07/21	101.72KB	Share
ATX	App 4G - Key to Corporate Governance Disclosures		23/07/21	404.25KB	Share
ATX	2021 Corporate Governance Statement		23/07/21	369.43KB	Share
ATX	Annual Report to Shareholders - YE 31 March 2021		23/07/21	1.23MB	Share
ATX	Notice of Annual General Meeting/Proxy Form		23/07/21	493.5KB	Share
ATX	Results from Successful Phase 1 Clinical Trial of AMP945	PRICE SENSITIVE	21/07/21	161.69KB	Share
ATX	Financial Report YE 31 March 2021 - Audited		29/06/21	1.24MB	Share
ATX	Amplia and Garvan Enter Into Collaboration Agreement	PRICE SENSITIVE	28/06/21	110.05KB	Share
ATX	Annual General Meeting to be Held 27 August 2021		25/06/21	99.06KB	Share
ATX	Change of Director's Interest - Dr. Lambert Exercise Options		08/06/21	363.87KB	Share
ATX	Application for quotation of securities - ATX		07/06/21	25.32KB	Share
ATX	Application for quotation of securities - ATX		07/06/21	24.79KB	Share
ATX	AMP945 Improves Survival in Pacnreatic Cancer Model	PRICE SENSITIVE	02/06/21	170.28KB	Share
ATX	Application for Quotation of Shares - Options Exercised		01/06/21	264.1KB	Share
ATX	App 4E - Preliminary Final Report YE 31 March 2021	PRICE SENSITIVE	31/05/21	327.33KB	Share
ATX	Change in substantial holding		11/05/21	244.37KB	Share
ATX	Section 708A Cleansing Notice - Share Placement		10/05/21	129.42KB	Share

ATX First Patient Recruited to ACCENT Trial in Pancreatic Cancer
02/08/22	PRICE SENSITIVE	132.49KB	Share
ATX Quarterly Activities and Cashflow Reports - June 2022 Qtr
28/07/22	PRICE SENSITIVE	371.69KB	Share
ATX Presentation at Major Pancreatic Cancer Conference
25/07/22		153.78KB	Share
ATX Notice of Annual General Meeting/Proxy - YE 31 March 2022
22/07/22		591.2KB	Share
ATX Change of Director's Interest Notice - Dr. Chistopher Burns
07/07/22		341.79KB	Share
ATX Change of Director's Interest Notice - Dr. Robert Peach
07/07/22		276.74KB	Share
ATX Change of Director's Interest Notice - Dr. John Lambert
07/07/22		467.75KB	Share
ATX Change of Director's Interest Notice - Dr. Warwick Tong
07/07/22		402.32KB	Share
ATX Notification of cessation of securities - ATX
05/07/22		21.69KB	Share
ATX Application for quotation of securities - ATX
30/06/22		24.91KB	Share
ATX Annual General Meeting to be held Thursday 25 August 2022
29/06/22		118.42KB	Share
ATX Registered Office and Principal Place of Business
24/06/22		127.54KB	Share
ATX Notification of Expiry of Unlisted Options
09/06/22		210.42KB	Share
ATX Application for quotation of securities - ATX
09/06/22		24.91KB	Share
ATX AMP945 Shows Efficacy in Model of Lung Fibrosis
02/06/22	PRICE SENSITIVE	182.84KB	Share
ATX App 4G - Key to Corporate Governance Disclosures
30/05/22		368.09KB	Share
ATX 2022 Corporate Governance Statement
30/05/22		396.46KB	Share
ATX Preliminary Final Report and Annual Report YE 31 March 2022
30/05/22	PRICE SENSITIVE	2.92MB	Share
ATX Amplia Receives Second Ethics Clearance for Phase 2 Trial
13/05/22	PRICE SENSITIVE	158.42KB	Share
ATX Amplia Presentation to 16th Bioshares Biotech Summit
12/05/22		10.4MB	Share
ATX AMP945 Pre-IND Meeting Outcome
09/05/22	PRICE SENSITIVE	133.54KB	Share
ATX Quarterly Activities and Cashflow Reports - March 2022 Qtr
19/04/22	PRICE SENSITIVE	380.29KB	Share
ATX Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
06/04/22	PRICE SENSITIVE	187.1KB	Share
ATX Notification of cessation of securities - ATX
05/04/22		21.66KB	Share
ATX AMP945 Improves Survival in Human Pancreatic Cancer Model
17/02/22	PRICE SENSITIVE	232.86KB	Share
ATX ATX Abstract accepted for presentation at Cancer Conference
15/02/22		154.44KB	Share
ATX Sale of Unmarketable Parcels of Shares
14/02/22		782.73KB	Share
ATX Change of Director's Interest Notice - Jane Bell
10/02/22		321.86KB	Share
ATX Amplia Investor Presentation - February 2022
01/02/22		11MB	Share
ATX Quarterly Activities and Cashflow Reports - Dec 2021 Qtr
24/01/22	PRICE SENSITIVE	412.91KB	Share
ATX Notification regarding unquoted securities - ATX
19/01/22		27.73KB	Share
ATX Amplia Completes Manufacture of AMP945 for Planned Trials
13/01/22	PRICE SENSITIVE	133.41KB	Share
ATX Change in substantial holding
23/12/21		138.28KB	Share
ATX Application for quotation of securities - ATX
22/12/21		24.88KB	Share
ATX Application for quotation of securities - ATX
22/12/21		24.93KB	Share
ATX Change in substantial holding
22/12/21		141.83KB	Share
ATX App 3Y - Change of Director's Interest - Mrs Jane Bell
21/12/21		322.38KB	Share
ATX App 3Y - Change of Director's Interest - Dr. Chris Burns
21/12/21		344.52KB	Share
ATX App 3Y - Change of Director's Interest - Dr. Robert Peach
21/12/21		348.92KB	Share
ATX App 3Y - Change of Director's Interest - Dr. John Lambert
21/12/21		365.41KB	Share
ATX App 3Y - Change of Directors Interest Notice - Dr. W. Tong
21/12/21		347.04KB	Share
ATX Proposed issue of securities - ATX
21/12/21		24.99KB	Share
ATX Update - Application for quotation of securities - ATX
20/12/21		26.44KB	Share
ATX Results of Extraordinary General Meeting
17/12/21		207.35KB	Share
ATX Amplia Provides Updated Investor Presentation
16/12/21	PRICE SENSITIVE	3.01MB	Share
ATX Change in substantial holding
15/12/21		201.39KB	Share
ATX Update - Application for quotation of securities - ATX
15/12/21		26.76KB	Share
ATX Update - Proposed issue of securities - ATX
14/12/21		36.06KB	Share
ATX Entitlement Offer Completed
10/12/21	PRICE SENSITIVE	105.92KB	Share
ATX Amplia Awarded $2.1M R&D Cash Flow Loan
02/12/21	PRICE SENSITIVE	131.38KB	Share
ATX App 4D and Financial Report Half Year ended 30 Sep 2021
24/11/21	PRICE SENSITIVE	868KB	Share
ATX Notice of Extraordinary General Meeting - 17 Dec 2021
19/11/21		525.78KB	Share
ATX Summary Results - Successful Phase 1 Clinical Trial AMP945
18/11/21		163.8KB	Share
ATX Inhibition of FAK by AMP945 in Phase 1 Clinical Trial
17/11/21	PRICE SENSITIVE	134.39KB	Share
ATX Becoming a substantial holder
16/11/21		80.04KB	Share
ATX Application for quotation of securities - ATX
15/11/21		25.31KB	Share
ATX Change in substantial holding
15/11/21		141.19KB	Share
ATX Application for quotation of securities - ATX
15/11/21		24.92KB	Share
ATX Section 708A Cleansing Notice - Share Placement
12/11/21		137.62KB	Share
ATX Blueflag Holding - Change of Interest of Substantial Holder
12/11/21		129.13KB	Share
ATX Application for quotation of securities - ATX
12/11/21		25.17KB	Share
ATX Proposed issue of securities - ATX
08/11/21		36.46KB	Share
ATX Proposed issue of securities - ATX
08/11/21		30.62KB	Share
ATX Capital Raising Investor Presentation
08/11/21	PRICE SENSITIVE	2.08MB	Share
ATX Entitlement Offer Prospectus
08/11/21	PRICE SENSITIVE	970.51KB	Share
ATX Placement and Underwritten Entitlement Offer to Raise $12.4m
08/11/21	PRICE SENSITIVE	230.26KB	Share
ATX Amplia and CRUK agree to Amend Licence Terms - AMP886
04/11/21		103.46KB	Share
ATX Trading Halt
04/11/21	PRICE SENSITIVE	234.65KB	Share
ATX Quarterly Activities and Cashflow Reports - Sep 2021 Qtr
27/10/21	PRICE SENSITIVE	346.77KB	Share
ATX Amplia Appoints New Oncology Clinical Advisor
26/10/21		130.94KB	Share
ATX Amplia Provides Updated Investor Presentation
19/10/21	PRICE SENSITIVE	2.44MB	Share
ATX Amplia Receives $1.1m R&D Tax Incentive
14/10/21	PRICE SENSITIVE	102.7KB	Share
ATX Amplia Appoints New Chief Financial Officer
01/10/21		100.18KB	Share
ATX New Garvan Publication Supports Amplia Phase 2 Design
30/09/21	PRICE SENSITIVE	158.96KB	Share
ATX Proactive Investors Lifesciences Webinar Presentation
28/09/21		1.16MB	Share
ATX Amplia to Present at Proactive Investor Lifesciences Webinar
27/09/21		106.94KB	Share
ATX Phase 2 Trial in First-Line Pancreatic Cancer Patients
15/09/21	PRICE SENSITIVE	134.22KB	Share
ATX Updated Investor Presentation
15/09/21		2.58MB	Share
ATX Change of Director's Interest Notice - Jane Bell
06/09/21		352.54KB	Share
ATX Results of Annual General Meeting
27/08/21		150.35KB	Share
ATX AGM - Chief Executive Officer's Presentatioin
27/08/21	PRICE SENSITIVE	1.4MB	Share
ATX Annual General Meeting Arrangements
20/08/21		104.63KB	Share
ATX Quarterly Activities and Cashflow Reports and Presentation
28/07/21	PRICE SENSITIVE	2.4MB	Share
ATX Shareholder Update and Presentation
26/07/21		101.72KB	Share
ATX App 4G - Key to Corporate Governance Disclosures
23/07/21		404.25KB	Share
ATX 2021 Corporate Governance Statement
23/07/21		369.43KB	Share
ATX Annual Report to Shareholders - YE 31 March 2021
23/07/21		1.23MB	Share
ATX Notice of Annual General Meeting/Proxy Form
23/07/21		493.5KB	Share
ATX Results from Successful Phase 1 Clinical Trial of AMP945
21/07/21	PRICE SENSITIVE	161.69KB	Share
ATX Financial Report YE 31 March 2021 - Audited
29/06/21		1.24MB	Share
ATX Amplia and Garvan Enter Into Collaboration Agreement
28/06/21	PRICE SENSITIVE	110.05KB	Share
ATX Annual General Meeting to be Held 27 August 2021
25/06/21		99.06KB	Share
ATX Change of Director's Interest - Dr. Lambert Exercise Options
08/06/21		363.87KB	Share
ATX Application for quotation of securities - ATX
07/06/21		25.32KB	Share
ATX Application for quotation of securities - ATX
07/06/21		24.79KB	Share
ATX AMP945 Improves Survival in Pacnreatic Cancer Model
02/06/21	PRICE SENSITIVE	170.28KB	Share
ATX Application for Quotation of Shares - Options Exercised
01/06/21		264.1KB	Share
ATX App 4E - Preliminary Final Report YE 31 March 2021
31/05/21	PRICE SENSITIVE	327.33KB	Share
ATX Change in substantial holding
11/05/21		244.37KB	Share
ATX Section 708A Cleansing Notice - Share Placement
10/05/21		129.42KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 24.0¢		Change 0.005(2.13%)		Mkt cap ! $116.7M

Open	High	Low	Value	Volume
24.0¢	24.5¢	22.5¢	$2.020M	8.588M

Buyers (Bids)

No.	Vol.	Price($)
10	230225	23.5¢

Sellers (Offers)

Price($)	Vol.	No.
24.0¢	778184	1

View Market Depth

No.	Vol.	Price($)
10	230225	0.235
10	1258647	0.230
15	758333	0.225
19	540605	0.220
3	287558	0.215

Price($)	Vol.	No.
0.240	778184	1
0.245	305000	5
0.250	145520	6
0.255	160816	3
0.260	117000	4

Last trade - 16.10pm 30/07/2025 (20 minute delay)


Last 23.5¢		Change 0.005 ( 0.51 %)
Open	High	Low	Volume
24.0¢	24.5¢	22.5¢	4282855
Last updated 15.59pm 30/07/2025 ?

ATX (ASX) Chart

AMPLIA THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available